Aberrant cytokeratin 7 expression by hepatocytes can predict the ductopenia grade in primary biliary cholangitis

作者：Hongli Liu, An-Yin Yang, Qing‐Fang Xiong, Yan-Dan Zhong, Du-Xian Liu, Ping Huang, Xiaoning Feng, Yu Zhang, Yongfeng Yang · 发表于：BMC Gastroenterology · 年份：2022 · DOI：10.1186/s12876-022-02538-w · 被引用次数：10 · 研究领域：Liver Diseases and Immunity、Pediatric Hepatobiliary Diseases and Treatments、Gallbladder and Bile Duct Disorders

Abstract Background Aberrant cytokeratin 7 expression by hepatocytes (CK7 + Hs) is the hallmark characteristic of cholestasis diseases, especially in ductopenia diseases such as primary biliary cholangitis (PBC). This study attempted to evaluate the differences and relationships between the clinical and histological features of aberrant cytokeratin 7 (CK7) expression by hepatocytes in PBC patients. Methods The clinicopathological data of patients diagnosed with PBC at the Second Hospital of Nanjing between January 2016 and September 2018 were analysed with SPSS 20.0. Results Eighty-nine PBC patients who underwent liver biopsy were enrolled in this study, and 15, 29 and 45 patients had aberrant CK7 expression by hepatocytes (CK7 + Hs (2 +), CK7 + Hs (1 +), and CK7 − Hs, respectively). There were significant differences in TB, DB, ALP, TA, IgM, interface activity, and ductopenia grade between patients with CK7 − Hs and CK7 + Hs (2 +) ( P < 0.05). The ductopenia grade was also significantly different between patients with CK7 + Hs (2 +) and CK7 + Hs (1 +) according to sex ( P < 0.05). Upon merging the data of CK7 + Hs (2 +) and CK7 + Hs (1 +) into CK7 + Hs, we found significant differences in AMA, AMA-M2, anti-gp210, TB, DB, ALP, TA, IgM, fibrosis, and ductopenia grade between CK7 + Hs and CK7 − Hs ( P < 0.05). The odds ratios (ORs) (and 95% confidence intervals (CIs)) of CK7 + Hs according to anti-gp210, ductopenia grade, and interface activity were 6.413 (95% CI 1.363...